Alerta

METHODS AND SYSTEMS FOR CONTROLLING AN INFUSION PUMP

Resumen de: US20260295159A1

A system for pairing a controller and an infusion pump is disclosed. The system includes an infusion pump, a controller device and a user interface residing on both the infusion pump and the controller. The user interface includes a pairing mode for enabling wireless communication between the infusion pump and the controller device, wherein the user interface requires both the infusion pump and the controller to be in the pairing mode simultaneously. Also, a method of changing a power source in an infusion pump is disclosed. The method includes placing the infusion pump in idle mode wherein the infusion pump stops delivery. Removing the first power source from the infusion pump. Replacing the first power source with a second power source in the infusion pump, and maintaining the insulin on board during the changing of the first power source with the second power source.

Ribosomal Remodeling in Diabetes

Resumen de: US20260295074A1

0000 This disclosure relates to ribosomal remodeling due to high glucose conditions. In some embodiments, translation of proteins in pancreatic beta-cells is altered based on the ribosomal remodeling. Means of increasing the percentage of large ribosomal subunit protein P1 (RPLP1) associated with ribosomes and/or decreasing the percentage of soluble RPLP1 in a cell to counteract effects of high glucose conditions in diabetes are disclosed.

IN VITRO GUT MODEL USING MUCIN-ANALOGS

Resumen de: US20260297531A1

This disclosure relates to an invitro gut model, including an integral layer of intestinal epithelial cells, an artificial mucus atop the integral layer of intestinal epithelial cells, wherein the artificial mucus comprises a silk glycopolymer and optionally a silk polymer lacking sugar substituents, the artificial mucus having a degree of substitution of the silk glycopolymer, a location of substitution of the silk glycopolymer, a concentration of the silk glycopolymer, an overall polymer concentration, an overall silk polymer concentration, an optional concentration of the silk polymer lacking sugar substituents, an optional ratio by weight of the silk glycopolymer and the silk polymer lacking sugar substituents, and/or a silk glycopolymer silk backbone molecular weight is tailored to maintain the integral layer of intestinal epithelial cells for a predetermined length of time, and growth media accessible to the intestinal epithelial cells and tailored to maintain viability of the intestinal epithelial cells.

GROWTH FACTOR SUBSTITUENTS

Resumen de: US20260297529A1

Growth-enhancing peptides and fusion polypeptide are provided. The peptides and fusion polypeptides may be used in cell culture, in particular in the production of cultured meat, as replacement or addition to insulin. There is further provided a cell culture medium comprising at least one of the peptides or fusion polypeptides, and a method for growing cells comprising adding at least one of the peptides or polypeptides to the cell culture medium.

BIOINTERFACE LAYER FOR ANALYTE SENSORS

Resumen de: EP4814115A2

Disclosed are devices for determining an analyte concentration (e.g., glucose). The devices comprise a sensor configured to generate a signal associated with a concentration of an analyte and a sensing membrane located over the sensor. The sensing membrane comprises a biointerface layer which interfaces with a biological fluid containing the analyte to be measured. The biointerface layer comprises a biointerface polymer, wherein the biointerface polymer comprises polyurethane and/or polyurea segments and one or more zwitterionic repeating units. The biointerface layer increases sensor longevity and decrease sensor inaccuracy by inhibiting accumulation of cells, proteins, and other biological species on the outermost layers of the sensor.

METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR CGM-BASED PREVENTION OF HYPOGLYCEMIA VIA HYPOGLYCEMIA RISK ASSESSMENT AND SMOOTH REDUCTION INSULIN DELIVERY

Resumen de: EP4814986A2

0001 An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

ASSESSMENT OF PAST INSULIN DELIVERY OUTCOMES TO AUTOMATICALLY TUNE MDA SYSTEMS

Resumen de: EP4814980A2

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

DISPOSABLE GLUCOSE BIOSENSOR INCLUDING AN ACTIVITY SENSOR

Resumen de: EP4813291A2

0001 Example disposable biosensor devices having an activity sensor are disclosed. One example device includes a disposable biosensor that has a first electrode having a distal end to be inserted into a subcutaneous layer beneath a person's skin, the first electrode having a reactive material disposed on the distal end, and a second electrode. The disposable biosensor device also includes an activity sensor that can be activated upon an activity by the person, the activity sensor for detecting the activity and providing data about the activity. The disposable biosensor also includes a radio frequency transmitter for transmitting data obtained from the first or second electrode and the activity sensor.

Methods of manufacturing electrochemical sensors

Resumen de: US12745932B1

An electrode system for an electrochemical sensor, such as a glucose sensor, is disclosed. The electrode system may include a working electrode, a reference electrode, and a counter electrode. The working electrode may comprise two layers of different metals, such as gold and platinum. A method for forming such an electrode system is disclosed.

Hybrides Aufmerksamkeitssystem für die genaue kontinuierliche Echtzeit-Blutzuckermessung bei Diabetes

Resumen de: DE202026105272U1

Ein hybrides Aufmerksamkeitssystem zur präzisen, kontinuierlichen Blutzuckermessung in Echtzeit bei Diabetes, bestehend aus:eine tragbare Sensoranordnung mit mindestens einem Glukosesensorelement zur kontinuierlichen Erfassung glukoseabhängiger elektrischer Signale aus einem interstitiellen Flüssigkeitsbereich des Benutzers, einer Hautkontaktschnittstelle zur Aufrechterhaltung eines stabilen Kontakts zwischen dem Glukosesensorelement und der Hautoberfläche sowie einem Temperatursensorelement zur Erzeugung von Temperaturmessungen am Messort;eine analoge Signalaufbereitungseinheit, die elektrisch mit der tragbaren Sensoreinheit verbunden ist und so konfiguriert ist, dass sie die glukoseabhängigen elektrischen Signale verstärkt, filtert, kompensiert und stabilisiert, um aufbereitete Sensorsignale zu erzeugen;eine Analog-Digital-Wandlereinheit, die so konfiguriert ist, dass sie die aufbereiteten Messsignale in sequentielle digitale Glukosemesswerte umwandelt;eine Einheit zur Erfassung physiologischer Parameter, die so konfiguriert ist, dass sie physiologische Messungen wie Hauttemperatur, Bewegungsinformationen, Gewebekontaktdruck und perfusionsbezogene Messungen am Messort empfängt;ein Speicher, der so konfiguriert ist, dass er sequentielle Glukosemessproben, physiologische Messwerte, historische Messdatensätze und Kalibrierungsinformationen speichert;ein Merkmalsgenerierungsprozessor, der so konfiguriert ist, dass er zeitliche Merkmalsdarstellungen und physiologische Me

Method for calibrating sensitivity for glucose measurement

Resumen de: NZ813952A

An embodiment may provide a method for calibrating sensitivity for glucose measurement including: obtaining an offset value for determining sensitivity; determining a first sensitivity from a sensor data and a reference glucose value, based on the offset value; and determining sensitivity by adjusting the first sensitivity, wherein the determining of the sensitivity includes obtaining one sensitivity, and determining sensitivity A by adjusting the one sensitivity by reflecting an average sensor data obtained by averaging a plurality of sensor data and an average glucose value obtained by averaging a plurality of glucose values to the one sensitivity; and determining the sensitivity A as the sensitivity.

MEDICAL INFUSION PUMP SYSTEM FOR THE DELIVERY OF AN INSULIN COMPOUND

Resumen de: WO2019193351A1

There is provided inter aliaa medical infusion pump system comprising a pump and a reservoir comprising an aqueous liquid pharmaceutical composition for delivery by means of said pump to a mammal wherein the composition comprises (i) an insulin compound at a concentration of 400 U/mLor more, (ii) ionic zinc and (iii) a non-ionic surfactant and wherein the said pump delivers the composition in pulses wherein the volume of the pulse is 0.5 µLor less.

Body attachable unit for continuous blood glucose measurement

Resumen de: NZ799606A

A body-attachable unit for continuous glucose measurement that includes an upper and lower case enclosing a PCB 530, communication chip 540, battery 535, and a sensor unit 520. The sensor unit 520 can be inserted into the body. Initially, the sensor and communication chip are disconnected while the battery 535 remains connected to the PCB 530. Switching to an active state (where sensor and chip are connected) occurs when a user-intended object approaches a specific region of the unit.

Methods of treating diabetes

Resumen de: NZ800826A

Described herein are doses and dosing regimens comprising determining and administering doses of long-acting insulin receptor agonists suitable for once-weekly dosing, such as Weekly Basal Insulin-Fc (BIF). In particular, the invention provides the use of insulin efsitora alfa/BIF for treating diabetes comprising an initial 3x loading dose followed by one or more once-weekly maintenance dose/s.

GLUCOSE MONITORING METHOD, AND DEVICE AND COMPUTER-READABLE STORAGE MEDIUM

Resumen de: WO2026194464A1

A glucose monitoring method, comprising: determining first information and second information, wherein the first information is a glucose monitoring result corresponding to a first time period, the second information is a target behavior type associated with the first time period, the target behavior type is one of user behavior types, and the user behavior types comprise one or more of an eating behavior type, an exercise behavior type or a sleep behavior type; and on the basis of the first information and the second information, generating first prompt information, wherein the first prompt information is used for prompting the glucose monitoring result associated with the target behavior type. The method can help a user achieve more precise and more effective glucose management.

USING CONTINUOUS BIOMETRIC INFORMATION MONITORING FOR SECURITY

Resumen de: US20260288926A1

0000 Measurements of biometric information of a user are obtained over time, such as blood glucose measurements. These biometric measurements are typically obtained by a wearable biometric information monitoring device being worn by the user. These biometric measurements are used by various different systems, such as a computing device of the user or a biometric information monitoring platform that receives biometric measurements from multiple different users. The biometric measurements are used for various security aspects, such as one or more of part of multi-factor authentication of the user, generating security keys (e.g., connection keys, encryption keys), identifying biometric measurements associated with different user identifiers but the same use, and protecting biometric measurements so as to be retrievable only by a recipient associated with an additional computing device, and so forth.

INSULIN INFUSION SET

Resumen de: US20260284305A1

0000 Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.

JOINT STATE ESTIMATION PREDICTION THAT EVALUATES DIFFERENCES IN PREDICTED VS. CORRESPONDING RECEIVED DATA

Resumen de: US20260290595A1

0000 Systems and methods are provided for reconciling untrusted data of a subject using trusted data pertaining to the subject. Systems and methods are directed to evaluating differences in predicted data with respect to corresponding received data. Systems and methods estimate metabolic states from a combination of trusted and untrusted metabolic inputs, along with optionally using a personalized mathematical model with parameter optimization. Systems and methods provide for reconciled untrusted inputs with their measured impact of the glycemic signals that is consistent with a metabolic model. Estimation of future metabolic states for decision support and automated insulin dosing is enabled. Replay of scenarios with estimated or reconciled data is also provided.

SYSTEMS AND METHODS FOR MONITORING AND TREATING DIABETIC FOOT ULCERS

Resumen de: US20260283539A1

0000 In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.

HEMOGLOBIN CONCENTRATION MEASUREMENT DEVICE, BLOOD GLUCOSE LEVEL MEASUREMENT DEVICE, AND HEMOGLOBIN CONCENTRATION MEASUREMENT METHOD

Resumen de: WO2026196765A1

This hemoglobin concentration measurement device comprises: a light output unit that outputs, to a living body, measurement light including at least light having a first wavelength and light having a second wavelength different from the first wavelength; a light detection unit that detects the measurement light transmitted through the living body; a signal acquisition unit that acquires, on the basis of a detection result of the light detection unit, a first signal relating to blood of the living body and a second signal relating to surrounding tissue other than the blood of the living body; and a hemoglobin concentration estimation unit that estimates a hemoglobin concentration on the basis of the first signal and the second signal acquired by the signal acquisition unit when a blood flow state of the living body is a first state, and the first signal and the second signal acquired by the signal acquisition unit when the blood flow state is a second state different from the first state.

SYSTEM AND METHOD FOR INFUSION SET DISLODGEMENT DETECTION

Resumen de: US20260284326A1

A portable insulin pump can utilize readings from a sensor incorporated into an infusion set used with the pump to deliver insulin to a patient to determine if the infusion set is or is likely to become dislodged from the patient. Readings from the sensor that are inconsistent with expected readings or a range of expected readings can indicate that the infusion set has become dislodged from the patient.

ADIPOCYTE GROWTH INHIBITOR

Resumen de: US20260283977A1

ProblemThe present invention provides a useful treatment tool for obesity-related adipogenesis using DHMBA. DHMBA-containing culture suppresses the growth of 3T3-L1 preadipocytes in vitro, leading to a reduction in the number of cells. In an adipocyte differentiation process, culture in the presence of DHMBA suppresses adipogenesis in the process of differentiation of 3T3-L1 preadipocytes into adipocytes through the regulation of various signaling processes associated with insulin signaling.SolutionThe present invention includes 3,5-dihydroxy-4-methoxy benzyl alcohol (DHMBA) as an active ingredient and has an inhibitory action on 3T3-L1 preadipocyte growth.

TCR WITH HIGH AFFINITY AND SPECIFICITY SPECIFIC FOR PREPROINSULIN PEPTIDE ALWGPDPAAA BOUND TO HLA-A2*02

Resumen de: US20260285984A1

The present invention relates to binding molecules comprising a peptide-major histocompatibility complex (pMHC)-binding domain which binds to a ALWGPDPAAA (SEQ ID NO: 1) peptide (derived from human pre-pro insulin (PPI) protein) presented as a peptide-HLA-A*02 complex. Said binding molecules may comprise CDR sequences embedded within a framework sequence. The CDRs and framework sequences may correspond to a T cell receptor (TCR) variable domain and may further comprise non-natural mutations relative to a native TCR variable domain. The binding molecules of the invention have high affinity and high specificity for the ALWGPDPAAA (SEQ ID NO: 1)-HLA-A*02 complex. The binding molecules may further comprise an immune suppressor and/or a half-life extending domain. Such binding molecules are particularly useful in the development of soluble immunotherapeutic reagents for the treatment of autoimmune diseases, such as diabetes.

CELL THERAPIES FOR TYPE 1 DIABETES

Resumen de: US20260285937A1

0000 The present disclosure is directed to T cell receptors targeting GAD65 and isolated cell populations comprising regulatory T cells exogenously expressing said TCRs used to treat Type 1 Diabetes.

ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR BETA-GAMMA AGONISTS

Nº publicación: US20260284145A1 24/09/2026

Solicitante:

SOTIO BIOTECH INC [US]
SOTIO BIOTECH AG [CH]
Sotio Biotech Inc.
Sotio Biotech AG

Resumen de: US20260284145A1

0000 A combined therapy for treating cancer in a subject, comprising an immune cell population and an Interleukin-2/Inter-leukin-15 receptor beta gamma (IL-2/IL-15Rβγ) agonist. The immune cell population comprises genetically engineered immune cells expressing or overexpressing a metabolism-regulating polypeptide, which may (a) improves glucose uptake activity; (b) modulates the Krebs cycle; (c) enhances lactate concentration; and/or (d) diverts or redirects glucose metabolites out of a glycolysis pathway.